Abstract: Disclosed is a microchip. The microchip of the present invention is characterized by comprising: a first plate; and a second plate coupled to the first plate to form a channel, wherein the first plate comprises: a channel cover part; a first connection part spaced apart from the outer periphery of the channel cover part by a certain distance; and a tensile strength generation connecting part for mutually connecting the channel cover part and the first connection part so that the channel cover part elastically contacts the channel region formed on the second plate when the first plate is coupled to the second plate. According to the present invention, the channel cover part forming the channel elastically contacts the channel region formed on the second plate, thereby providing a microchip capable of providing a channel having a stable structure.

Abstract: A method of deciding detachment time of cells, and a method and apparatus for subculturing the cells using the method. The method of deciding detachment time of the cells from a culturing vessel using a separation enzyme in subculturing the cells includes: a photographing step of photographing an image of the cells treated with the enzyme; a computing step of calculating a contrast value of the photographed image, and computing a change rate of the contrast value; a comparison step of repeating the photographing step and the computing step until an increasing change rate of the contrast value is reduced to a predetermined change rate or less; and a reporting step of reporting a time to remove the enzyme from the cells and to detach the cells from the culturing vessel when the increasing change rate of the contrast value is reduced to the predetermined change rate or less.

Abstract: Provided herein is a pipette tip (600) for electroporation including an outer surface, a void (611) located within the outer surface, and a conductor (622) located at least partially on or within the outer surface, in electrical communication with at least a portion of the outer surface and the void. Further provided herein is a pipette tip for electroporation including a body, a connector (620), and an elongated part (630). The connector is located at the distal end of the body and further includes at least one connecting post, a connecting part in mechanical communication with the connector, and a conductor located at least partially on or within the connector, wherein the conductor surrounds at least a portion of the connecting post. The elongated part also has a void and is located at the distal end of the connector. The void of the body, connector, and elongated part are in fluid communication.

Abstract: Disclosed is a microscope module. The microscope module includes an objective lens magnifying an image of a sample subject for observation; an observation part for observing the image of the sample magnified through the objective lens; and a reflective mirror provided between the objective lens and the sample such that the vertical distance between the sample and the objective lens is substantially reduced. Since the reflective lens is disposed between the objective lens and the observation part, the working distance from the sample to the objective lens is substantially reduced, so that the height of the microscope is remarkably reduced. Thus, the microscope may be used in a place with vertical spatial limitations.

Abstract: An electroporation apparatus comprising an elongated hollow member in order to provide a uniform electric field during electroporation, wherein specifically, electroporation is carried out by applying electric pulses through a couple of electrodes from both end parts of the elongated hollow member, after the hollow member is charged with fluid specimen including cells and material which would be injected into the cells.

Abstract: The present invention relates to a diagnosis method of cancer using SYG972 gene and to the genomic DNA and to a promoter regulating transcription of the gene. Expression of SYG972 gene is greatly reduced in breast cancer cells compared to normal breast cells. Therefore the present invention provides a method of diagnosis method by using the gene of the present invention or its fragments as a probe. SYG972 genomic according to the present invention is composed of 4 exons and 3 introns. Promoter is 3 kb long from the transcription initiating site in the 5′ direction. SYG972 genomic DNA and promoter can be used to design and screen drugs to promote or to inhibit apoptosis and differentiation of cells, especially to screen drugs to treat cancer, a disease wherein cell growth and differentiation is abnormal.

Abstract: The present invention relates to a novel use of histone and an active fragment thereof and provides a pharmaceutical composition containing histone as an active ingredient to improve the symptoms of progressive, inflammatory and autoimmune arthritis. The pharmaceutical composition of the present invention includes histone, especially histone H1, histone H2A, histone H2B, histone H3, histone H4, an active fragment thereof, and a mixture thereof as an active ingredient, and could include pharmacologically approved carriers if necessary. Histone or its active fragment lowered induction of arthritis and reduced arthritis index more effectively than steroidal dexamethasone and also had a significant preventive effect.

Abstract: The present invention relates to a vector comprising P972 (also referred to as Gadd45&ggr;, CR6 or OIG37) gene known as a gene producing a cell growth-inhibiting protein for the treatment of cancers, an recombinant adenovirus that encodes P972 gene in the cell, a method of producing the above adenovirus and a method for the treatment of cancers by using the above vector or adenovirus. The recombinant adenovirus of the present invention can be used in the treatment of various cancers including cervical cancer, breast cancerand colon cancer.

Abstract: The present invention relates to a diagnosis method of cancer using SYG972 gene and to the genomic DNA and to a promoter regulating transcription of the gene. Expression of SYG972 gene is greatly reduced in breast cancer cells compared to normal breast cells. Therefore the present invention provides a method of diagnosis method by using the gene of the present invention or its fragments as a probe. SYG972 genomic according to the present invention is composed of 4 axons and 3 introns. Promoter is 3 kb long from the transcription initiating site in the 5′ direction. SYG972 genomic DNA and promoter can be used to design and screen drugs to promote or to inhibit apoptosis and differentiation of cells, especially to screen drugs to treat cancer, a disease wherein cell growth and differentiation is abnormal.

Abstract: The present invention relates to a novel use of histone and provides a pharmaceutical composition containing histone as an active ingredient to improve the symptoms of progressive, inflammatory and autoimmune arthritis. The pharmaceutical composition of the present invention includes histone, especially histone H1 as an active ingredient, and could include pharmacologically approved carriers if necessary. Histone H1 lowered induction of arthritis and reduced arthritis index more effectively than steroidal dexamethasone and also had a significant preventive effect.